Table 3 Factors associated with increased risk of TEEs in patients with ROS1 rearranged NSCLC
Variables | Number of patients (%) | Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|---|---|
With TEEs (n = 11) | Without TEEs (n = 36) | χ2 | P value | sHR (95% CI) | P value | |
Age | 1.9528 | 0.162 | ||||
< 60 | 8(73) | 23(64) | ||||
≥ 60 | 3(27) | 13(36) | ||||
Sex | 1.7999 | 0.180 | ||||
Male | 6(55) | 14(39) | ||||
Female | 5(45) | 22(61) | ||||
Body-mass index | 1.0295 | 0.310 | ||||
< 23 kg/m2 | 4(36) | 19(53) | ||||
≥ 23 kg/m2 | 7(64) | 17(47) | ||||
Performance status | 0.6107 | 0.435 | ||||
0–1 | 3(27) | 25(69) | ||||
≥ 2 | 8(73) | 11(31) | ||||
Charlson Comorbidity Index | 1.8064 | 0.405 | ||||
0 | 4(36) | 8(22) | ||||
1–2 | 5(45) | 20(56) | ||||
≥ 3 | 2(18) | 8(22) | ||||
Smoke History | 0.4280 | 0.513 | ||||
Current and Former | 4(36) | 12(33) | ||||
Never | 7(64) | 24(67) | ||||
Number of metastatic sites | 0.7639 | 0.382 | ||||
1–2 | 7(64) | 25(69) | ||||
≥ 3 | 4(36) | 11(31) | ||||
Metastatic sites | ||||||
Brain | 0(0) | 6(17) | 0.8833 | 0.347 | ||
Liver | 1(10) | 1(3) | 0.1264 | 0.722 | ||
Lung | 3(30) | 9(25) | 0.0049 | 0.944 | ||
Adrenal | 1(10) | 3(8) | 0.8671 | 0.352 | ||
Soft tissue | 0(0) | 2(6) | 0.2604 | 0.610 | ||
Bone | 2(20) | 11(31) | 1.5584 | 0.212 | ||
Pleural | 6(55) | 16(44) | 1.2828 | 0.257 | ||
Lymph node | 11(100) | 23(64) | 1.9578 | 0.162 | ||
Baseline laboratory values | ||||||
Leukocyte count>5.61 × 109/L | 0.8359 | 0.361 | ||||
Neutrophil count>4.06 × 109/L | 1.5768 | 0.209 | ||||
Hemoglobin ≤143 g/L | 1.8735 | 0.171 | ||||
Platelet count >220 × 109/L | 0.8769 | 0.349 | ||||
CEA>4.52 ng/ml | 0.3222 | 0.570 | ||||
LDH>312 U/L | 13.5355 | < 0.001 | 1.0 (1.00–1.01) | 0.13 | ||
CRP>18.9 mg/L | 2.2882 | 0.130 | 1.0 (0.98–1.03) | 0.79 | ||
D-dimer>7.8μg/ml | 5.0609 | 0.02 | 1.16 (1.08–1.24) | < 0.001 | ||